Lipocine reported a FY 2025 net loss of USD 9.6 million, or USD 1.69 per diluted share, compared with net income of USD 8,352 a year earlier. FY 2025 revenue fell 82% to USD 2 million, mainly reflecting lower license revenue; royalty revenue from TLANDO sales rose 60% to USD 476,677. FY 2025 R&D expenses increased 16% to USD 8.6 million due to higher clinical study costs and higher supplies, research and personnel costs, while G&A expenses fell 25% to USD 3.8 million on lower business development, advisory, legal and insurance costs. Unrestricted cash, cash equivalents and marketable investment securities were USD 14.9 million at Dec. 31, 2025, and USD 24.7 million as of March 6, driven primarily by share sales under its ATM offering. In a Phase 3 confirmatory trial of postpartum depression candidate LPCN 1154, the last patient completed the final study visit in February, and topline results are expected in early April with an NDA submission anticipated in mid-2026 if successful.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lipocine Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-009428), on March 10, 2026, and is solely responsible for the information contained therein.